Takeda Pharmaceutical (TAK) Free Cash Flow (2018 - 2026)

Takeda Pharmaceutical's Free Cash Flow history runs 9 years deep, the most recent figure standing at -$373.4 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 56.4% year-over-year to -$373.4 million in Q1 2026; TTM through Mar 2026 was $7.0 billion, a 23.72% increase from a year earlier, with the FY2026 full-year figure at $6.9 billion, up 22.65% from the prior year.
• Free Cash Flow retreated to -$373.4 million in Q1 2026 per TAK's latest filing, from $2.7 billion in the prior quarter.
• Across five years, Free Cash Flow topped out at $2.9 billion in Q4 2022 and bottomed at -$856.3 million in Q1 2025.
• The 5-year median for Free Cash Flow is $1.5 billion (2024), against an average of $1.4 billion.
• Across the five-year window, Free Cash Flow surged 115.45% in 2024 and plunged 357.85% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at $2.9 billion in 2022, then tumbled by 55.07% to $1.3 billion in 2023, then soared by 115.45% to $2.8 billion in 2024, then dropped by 4.43% to $2.7 billion in 2025, then plunged by 113.85% to -$373.4 million in 2026.
• Per Business Quant, the three latest TAK Free Cash Flow figures stand at -$373.4 million (Q1 2026), $2.7 billion (Q4 2025), and $2.8 billion (Q3 2025).